Current Progressive Cattle digital edition

Vista vaccine reintroduced into the market

Intervet Schering-Plough Animal Health Published on 28 February 2011

Intervet Schering-Plough Animal Health reintroduced the Vista® vaccine line in January, to provide beef cattle veterinarians and producers with complete protection against the most common and costly bovine respiratory and reproductive diseases.

Vista vaccines protect beef cattle against Infectious Bovine Rhinotracheitis (IBR), Bovine Viral Diarrhea (BVD Type 1 and Type 2), Parainfluenza3 (PI3), Bovine Respiratory Syncytial Virus (BRSV), leptospirosis, vibriosis, Mannheimia haemolytica and Pasteurella multocida.

The Vista line of vaccines was introduced to the market in 2005. A stop sale was issued on the vaccine in 2009 due to a variability issue with the BRSV antigen.

Intervet Schering-Plough Animal Health worked with the U.S. Department of Agriculture to resolve the issue and welcomed back this cattle vaccine to its portfolio and the market with additional research that confirms its respiratory and reproductive disease protection.

Vista provides complete protection from bovine respiratory disease (BRD), commonly known as pneumonia, which is the most prevalent disease in calves older than 30 days.

Long-term effects of pneumonia include a negative impact on growth, reproductive performance and longevity.

Vista Once SQ is the only avirulent-live culture Mannheimia haemolytica/Pasteurella multocida protection combined with a MLV five-way viral.

Mannheimia haemolytica and Pasteurella multocida are common causes of BRD, and Vista’s unique avirulent-live technology helps lead to a more complete immune response.

Vista also provides protection from reproductive diseases in cattle, including IBR, BVD Type 1, BVD Type 2, leptospirosis and vibriosis.

Reproductive diseases can cause poor conception rates, abortions and reduced calving percentages.

Vista is the only vaccine labeled for BVD Type 1 and Type 2 protection throughout the entire pregnancy, offering complete fetal protection.

Vista provides protection for both persistent infection, for less than 120 days of gestation and for fetal (or congenital) infection, after 120 days of gestation.

—Intervet Schering-Plough news release